Associations between prescription opioid injection and Hepatitis C virus among young injection drug users

Drugs: Education, Prevention and Policy

Volumn 22, Issue 1, 2015, Pages 35-42

  Lankenau, Stephen ^a   Kecojevic, Aleksandar ^b   Silva, Karol ^c  

^a DREXEL UNIVERSITY   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Hepatitis C virus; Injection drug use; Opiates

Indexed keywords

EID: 84920973908     PISSN: 09687637     EISSN: 14653370     Source Type: Journal    
DOI: 10.3109/09687637.2014.970515     Document Type: Article

References (50)

1. Alter, M.J., Gerety, R.J., Smallwood, L., Sampliner, R.E., Tabor, E., Deinhardt, F. Matanoski, G.M. (1982). Sporadic non-A, non-B hepatitis: Frequency and epidemiology in an urban U.S. population. The Journal of Infectious Diseases, 145, 886-893.
2. Barros, A.J., & Hirakata, V.N. (2003). Alternatives for logistic regression in cross-sectional studies: An empirical comparisson of models that directly estimate the prevalence ratio. BMC Medical Research Methodology, 3, 21.
3. Bell, J., Batey, R.G., Farrell, G.C., Crewe, E.B., Cunningham, A.L., & Byth, K. (1990). Hepatitis C virus in intravenous drug users. The Medical Journal of Australia, 153, 274-276.
4. Biernacki, P., & Waldorf, D. (1981). Snowball sampling: Problems, techniques and chain-referral sampling. Sociological Methods and Research, 10, 141-163.
5. Black, R.A., Trudeau, K.J., Cassidy, T.A., Budman, S.H., & Butler, S.F. (2013). Associations between public health indicators and injecting prescription opioids by prescription opioid abusers in substance abuse treatment. Journal of Opioid Management, 9, 5-17.
6. Bruneau, J., Roy, É ., Arruda, N., Zang, G., & Jutras-Aswad, D. (2012). The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction, 107, 1318-1327.
7. Centers for Disease Control and Prevention. (2008). Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users-New York, November 2004-April 2007. Morbidity And Mortality Weekly Report, 57, 517-521.
8. Centers for Disease Control and Prevention. (2011). Hepatitis C virus infection among adolescents and young adults-Massachusetts 2002-2009. Morbidity And Mortality Weekly Report, 60, 537-541.
9. Clatts, M., Colon-Lopez, V., Giang le, M., & Goldsamt, L. (2010). Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection. Journal of Urban Health, 87, 278-291.
10. Creswell, J.P. (2006). Mixed methods design. Thousand Oaks, CA: Sage.
11. Davis, W.R., & Johnson, B.D. (2008). Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug and Alcohol Dependence, 92, 267-276.
12. Day, C., White, B., Thein, H., Doab, A., Dore, G., Bates, A. Maher, L. (2008). Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care, 20, 116-123.
13. Firestone, M., & Fischer, B. (2008). A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: Behaviours, preferences and drug availability. Harm Reduction Journal, 5, 30.
14. Fischer, B., Patra, J., Cruz, M.F., Gittins, J., & Rehm, J. (2008). Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug and Alcohol Review, 27, 625-632.
15. Garfein, R., & Doherty, M. (1998). Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. JAIDS, 18, 11-19.
16. Garfein, R., Vlahov, D., Galai, N., Doherty, M., & Nelson, K. (1996). Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health, 86, 655-661.
17. Hagan, H., Campbell, J., Thiede, H., Strathdee, S., Ouellet, L., Kapadia, F. Garfein, R.S. (2006). Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Reports, 121, 710-719.
18. Hagan, H., Des Jarlais, D., Stern, R., Lelutiu-Weinberger, C., Scheinmann, R., Strauss, S., & Flom, P.L. (2007). HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. International Journal of Drug Policy, 18, 341-351.
19. Hagan, H., Pouget, E.R., Williams, I.T., Garfein, R.S., Strathdee, S.A., Hudson, S.M. Ouellet, L.J. (2010). Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. Journal of Infectious Diseaes, 201, 378-385.
20. Hahn, J.A., Page-Shafer, K., Lum, P.J., Bourgois, P., Stein, E., Evans, J.L. Moss, A.R. (2002). Hepatitis C virus seroconversion among young injection drug users: Relationships and risks. Journal of Infectious Diseases, 186, 1558-1564.
21. Havens, J.R., Lofwall, M.R., Frost, S.D.W., Oser, C.B., Leukefeld, C.G., & Crosby, R.A. (2013). Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. American Journal of Public Health, 103, e44-e52.
22. Horyniak, D., Dietze, P., Degenhardt, L., Higgs, P., McIlwraith, F., Alati, R. Burns, L. (2013). The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug Alcohol Dependence, 132, 541-546.
23. Johnson, K., Fibbi, M., Langer, D., Silva, K., & Lankenau, S. (2013). Prescription drug misuse and risk behaviors among young adult IDUs. Journal of Psychoactive Drugs, 45, 112-121.
24. Jones, C.M., Mack, K.A., & Paulozzi, L.J. (2013). Pharmaceutical overdose deaths, United States, 2010. JAMA, 309, 657-659.
25. Kirsh, K., Peppin, J., & Coleman, J. (2012). Characterization of prescription opioid abuse in the United States: Focus on route of administration. Journal of Pain & Palliative Care Pharmacotherapy, 26, 348-361.
26. Klevens, R.M., Hu, D.J., Jiles, R., & Holmberg, S.D. (2012). Evolving epidemiology of hepatitis C virus in the United States. Clinical Infectious Diseases, 55, S3-S9.
27. Krieger, N., Williams, D.R., & Moss, N.E. (1997). Measuring social class in US public health research: Concepts, methodologies, and guidelines. Annual Review of Public Health, 18, 341-378.
28. Lankenau, S., & Clatts, M. (2005). Patterns of polydrug use among ketamine injectors in New York City. Substance Use & Misuse, 40, 1381-1397.
29. Lankenau, S., Schrager, S., Silva, K., Kecojevic, A., Jackson Bloom, J., Wong, C., & Iverson, E. (2012). Prescription and illicit drug use among high-risk young adults in Los Angeles and New York. Journal of Public Health Research, 1, 1-9.
30. Lankenau, S., Teti, M., Silva, K., Jackson Bloom, J., Harocopos, A., & Treese, M. (2012a). Patterns of prescription drug misuse among young injection drug users. Journal of Urban Health, 89, 1004-1016.
31. Lankenau, S., Teti, M., Silva, K., Jackson Bloom, J., Harocopos, A., & Treese, M. (2012b). Initiation into prescription opioid misuse amongst young injection drug users. International Journal on Drug Policy, 23, 37-44.
32. Lankenau, S., Wagner, K., Jackson Bloom, J., Sanders, B., Hathazi, D., & Shin, C. (2010). The first injection event: Differences among heroin, methamphetamine, cocaine, and ketamine initiates. Journal of Drug Issues, 40, 241-262.
33. Ly, K.N., Xing, J., Klevens, R.M., Jiles, R.B., & Ward, J.W. (2012). The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of Internal Medicine, 156, 271-278.
34. Mickey, J., & Greenland, S. (1989). A study of the impact of confounderselection criteria on effect estimation. American Journal of Epidemiology, 129, 125-137.
35. Miller, C.L., Johnston, C., Spittal, P.M., Li, K., Laliberté, N., Montaner, J.S.G., & Schechter, M.T. (2002). Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology, 36, 737-742.
36. O'Keefe, D., Aitken, C., Higgs, P., & Dietz, P. (2013). Concordance between self-reported and actual hepatitis C virus infection status in a cohort of people who inject drugs. Drug and Alcohol Review, 32, 208-210.
37. Okie, S. (2010). A flood of opioids, a rising tide of deaths. New England Journal of Medicine, 363, 1981-1985.
38. Paulozzi, L. (2012). Prescription drug overdose: A review. Journal of Safety Research, 43, 283-289.
39. Roy, E., Arruda, N., & Bourgois, P. (2011). The growing popularity of prescription opioid injection in downtown Montreál: New challenges for harm reduction. Substance Use & Misuse, 46, 1142-1150.
40. Roy, E., Arruda, N., Leclerc, P., Haley, N., Bruneau, J., & Boivin, J.F. (2012). Injection of drug residue as a potential risk factor for HCV acquisition among Montreál young injection drug users. Drug and Alcohol Dependence, 126, 246-250.
41. Substance Abuse and Mental Health Services Administration (2011). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration.
42. Surratt, H., Kurtz, S.P., & Cicero, T.J. (2011). Alternate routes of administration and risk for HIV among prescription opioid abusers. Journal of Addictive Diseases, 30, 334-341.
43. Tabachnick, B.G., & Fidell, L.S. (2006). Using multivariate statistics (5th ed.). Needham Heights, MA: Allyn and Bacon.
44. Thorpe, L.E., Ouellet, L.J., Hershow, R., Bailey, S.L., Williams, I.T., Williamson, J. Garfein, R.S. (2002). Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology, 155, 645-653.
45. U.S. Deparment of Justice. (2008). Appalachia: High intensity drug trafficking area. National Intelligence Drug Center.
46. Valdiserri, R., Khalsa, J., Dan, C., Holmberg, S., Zibbell, J., Holtzman, D. Compton, W. (2014). Confronting the emerging epidemic of HCV infection among young injection drug users. American Journal of Public Health, 104, 816-821.
47. van den Hoek, J.A.H., van Haastrecht, H.J.A., Goudsmit, J., de Wolf, F., & Coutinho, R.A. (1990). Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. Journal of Infectious Diseases, 162, 823-826.
48. Watters, J.K., & Biernacki, P. (1989). Targeted sampling: Options for the study of hidden populations. Social Problems, 36, 416-430.
49. Zhang, J., & Yu, K.F. (1998). What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA, 280, 1690-1691.
50. Zou, G. (2004). A modified poisson regression approach to prospective studies with binary data. American Journal of Epidemiology, 159, 702-706.